Evidence map›Paper›PMID 39534882›Full record

ArticleMolecular and clinical oncology2025

Evaluation of glypican‑3 in patients with hepatocellular carcinoma.

Batchimeg Batbaatar, Unenbat Gurbadam, Odonchimeg Tuvshinsaikhan, Nyam-Erdene Narmandakh, Gerelee Khatanbaatar, Munkhbat Radnaabazar, Dulguun Erdene-Ochir, Minjuur Boldbaatar, Munkhdelger Byambaragchaa, Yerbolat Amankyeldi and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Batchimeg BatbaatarDepartment of Molecular biology and Genetics, School of Bio Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Unenbat GurbadamNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Odonchimeg TuvshinsaikhanInstitute of Medical Sciences, Mongolian National University of Medical Sciences, The Third Central Hospital, Ulaanbaatar 16081, Mongolia.
Nyam-Erdene NarmandakhInstitute of Medical Sciences, Mongolian National University of Medical Sciences, The Third Central Hospital, Ulaanbaatar 16081, Mongolia.
Gerelee KhatanbaatarNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Munkhbat RadnaabazarNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Dulguun Erdene-OchirNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Minjuur BoldbaatarNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Munkhdelger ByambaragchaaNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Yerbolat AmankyeldiNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Munkhzaya ChogsomNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Nyamsuren GanbilegNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Amgalantuul BatdelgerNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Tserendorj DemchigNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Lkham Nyam-OsorNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Batsaikhan BayartugsNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Enkhtsatsral BatmunkhNational Cancer Center of Mongolia, Ulaanbaatar 13370, Mongolia.
Batkhishig MunkhjargalInstitute of Medical Sciences, Mongolian National University of Medical Sciences, The Third Central Hospital, Ulaanbaatar 16081, Mongolia.
Tulgaa LonjidInstitute of Medical Sciences, Mongolian National University of Medical Sciences, The Third Central Hospital, Ulaanbaatar 16081, Mongolia.
Batbayar KhasbaganaInstitute of Biomedical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Munkhbat BatmunkhSchool of Medicine, International University of Health and Welfare, Narita, Chiba 286-8686, Japan.
Sarantuya JavDepartment of Molecular biology and Genetics, School of Bio Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar 14210, Mongolia.
Munkhbayar SemchinInstitute of Medical Sciences, Mongolian National University of Medical Sciences, The Third Central Hospital, Ulaanbaatar 16081, Mongolia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers occurring worldwide, including Mongolia. Although alpha-fetoprotein (AFP) is a widely used marker for HCC, conflicting studies have been published regarding its specificity and sensitivity towards HCC. Glypican-3 (GPC3) is a different promising biomarker for HCC, and there is some evidence to suggest that this protein may be a more specific marker compared with AFP. GPC3 has been shown to fulfill important roles in cell proliferation and division during embryogenesis, and is rarely found in the tissues of healthy adults. The aim of the present study was to investigate the levels of serum GPC3 (sGPC3) and tissue GPC3 in Mongolian patients with HCC. Serum samples from a total of 270 individuals [HCC group, 90 patients; risk group (RG), 90 subjects; and control group, 90 subjects] were evaluated using enzyme-linked immunosorbent assay to identify the sGPC3 levels. In addition, immunohistochemical analysis of the GPC3 was performed on tissue samples from 50 patients with HCC to evaluate the expression of GPC3. sGPC3 level was found to be significantly increased in the HCC group compared with the RG and the control group, with the area under the curve=0.85 (P<0.001). sGPC3 was found to be significantly associated with hepatitis C virus status and cirrhosis (P<0.05). In addition, the tissue expression of GPC3 was associated with the serum AFP (sAFP) level. Finally, positive staining of GPC3 was observed when the sAFP level of the patient was >20 ng/ml. In conclusion, the results from the present study have supported that GPC3 may be a promising marker for HCC, and can be used as a diagnostic marker alongside AFP.

Indexed as

biomarkerearly detectionglypican-3hepatocellular carcinoma

Identifiers

PMID39534882
PMCPMC11552472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.